New inhaled drug for cystic fibrosis enters human testing
Disease control
Recruiting now
This study is the first time the drug RCT2100 is being tested in humans. It aims to check the safety and tolerability of single and multiple doses in healthy adults and people with cystic fibrosis (CF). The trial will also see how the drug spreads in the body and gather early pro…
Phase: PHASE2 • Sponsor: ReCode Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC